Donor lymphocyte infusion after allogeneic stem cell transplantation

Luca Castagna, Barbara Sarina, Stefania Bramanti, Paolo Perseghin, Jacopo Mariotti, Lucio Morabito

Research output: Contribution to journalArticlepeer-review


Allogeneic stem cell transplantation (allo-SCT) is considered the cornerstone in the treatment of several malignant and not malignant hematological diseases. However, relapse of hematological disease after allo-SCT is considered the most challenging point in the field. The risk can be reduced through optimal patients, donor and disease selection before allo-SCT, but harnessing donor immune system is an appealing way to treat or avoid disease relapse. Donor lymphocyte infusion (DLI) is a simple and effective therapy after allo-SCT. In this paper, the efficacy of DLI will be analyzed in different hematological diseases, focusing also on their therapeutic or pre-emptive use.

Original languageEnglish
Pages (from-to)345-355
Number of pages11
JournalTransfusion and Apheresis Science
Issue number3
Publication statusPublished - Jun 1 2016


  • Allogeneic transplantation
  • DLI
  • Hematological disease
  • Pre-emeptive
  • Relapse

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Donor lymphocyte infusion after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this